New Small-Molecule Drugs Could Enhance Immune Responses to Cancer

Regen BioPharma’s candidates inhibit NR2F6 and activate human immune cells ex-vivo.

The NR2F6 nuclear receptor has been identified as a potentially important immune checkpoint inhibitor and has also been found to play role in cancer stem cell differentiation. Regen BioPharma, a California-based biotechnology company focused on stem cell and immunotherapies for specialty niche treatments are currently working on the advancement of small-molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.

The company is working to identify antagonists of NR2F6 that will lead to the enhancement of a patient’s own immune response. It also is looking for agonists that suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

Recently, Regen announced that it has developed several small-molecule inhibitors of NR2F6 that also activate human immune cells ex-vivo.

"Based on the known activities of NR2F6, we expect that inhibiting its activity will lead to increased T cell activation. We found that several of our NR2F6 antagonists can activate human immune cells, such as T cells, leading to increased IL-17a production in a concentration-dependent manner," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. 



Cynthia A. Challener, Ph.D.

Dr. Challener is an established industry editor and technical writing expert in the areas of chemistry and pharmaceuticals. She writes for various corporations and associations, as well as marketing agencies and research organizations, including That’s Nice and Nice Insight.